-$0.54 Earnings Per Share Expected for Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) This Quarter

Wall Street brokerages expect that Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) will announce earnings of ($0.54) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Eiger BioPharmaceuticals’ earnings. The highest EPS estimate is ($0.50) and the lowest is ($0.58). Eiger BioPharmaceuticals reported earnings of ($0.60) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 10%. The company is scheduled to report its next earnings results on Thursday, August 5th.

On average, analysts expect that Eiger BioPharmaceuticals will report full-year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($2.08) to ($0.64). For the next year, analysts expect that the business will post earnings of ($1.68) per share, with EPS estimates ranging from ($1.74) to ($1.57). Zacks’ EPS calculations are an average based on a survey of analysts that follow Eiger BioPharmaceuticals.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Thursday, May 6th. The biotechnology company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.02. The company had revenue of $3.65 million for the quarter, compared to the consensus estimate of $0.97 million.

A number of research firms have issued reports on EIGR. boosted their price objective on shares of Eiger BioPharmaceuticals from $23.00 to $26.00 in a report on Tuesday, May 11th. Citigroup boosted their price objective on shares of Eiger BioPharmaceuticals from $23.00 to $26.00 in a report on Tuesday, May 11th. Finally, Zacks Investment Research raised shares of Eiger BioPharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, June 28th.

NASDAQ EIGR traded down $0.16 during trading on Thursday, reaching $8.16. The company’s stock had a trading volume of 2,253 shares, compared to its average volume of 221,373. The company has a quick ratio of 9.62, a current ratio of 9.70 and a debt-to-equity ratio of 0.25. Eiger BioPharmaceuticals has a 12 month low of $7.57 and a 12 month high of $13.49. The company has a 50 day moving average of $8.19.

A number of hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. increased its position in Eiger BioPharmaceuticals by 8.1% during the 4th quarter. American International Group Inc. now owns 17,781 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 1,338 shares in the last quarter. Weiss Multi Strategy Advisers LLC increased its position in Eiger BioPharmaceuticals by 1.2% during the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 200,000 shares of the biotechnology company’s stock worth $1,770,000 after purchasing an additional 2,453 shares in the last quarter. JPMorgan Chase & Co. increased its position in Eiger BioPharmaceuticals by 1.4% during the 4th quarter. JPMorgan Chase & Co. now owns 203,477 shares of the biotechnology company’s stock worth $2,500,000 after purchasing an additional 2,801 shares in the last quarter. DAVENPORT & Co LLC increased its position in Eiger BioPharmaceuticals by 1.1% during the 1st quarter. DAVENPORT & Co LLC now owns 282,500 shares of the biotechnology company’s stock worth $2,500,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Eiger BioPharmaceuticals by 13.9% during the 4th quarter. Rhumbline Advisers now owns 28,067 shares of the biotechnology company’s stock worth $345,000 after purchasing an additional 3,430 shares in the last quarter. Institutional investors and hedge funds own 69.12% of the company’s stock.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.

Read More: Put Option Volume

Get a free copy of the Zacks research report on Eiger BioPharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.